USA - NASDAQ:GTBP - US36254L3087 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to GTBP. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-02 | Roth MKM | Initiate | Buy |
| 2023-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-07 | EF Hutton | Reiterate | Hold -> Hold |
| 2023-06-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-16 | EF Hutton | Reiterate | Hold -> Hold |
| 2023-04-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-31 | EF Hutton | Reiterate | Hold |
| 2023-01-05 | EF Hutton | Initiate | Hold |
| 2022-09-13 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-24 | HC Wainwright & Co. | Initiate | Buy |
| 2021-04-13 | B. Riley FBR | Initiate | Buy |
| 2021-03-17 | Roth Capital | Initiate | Buy |
7 analysts have analysed GTBP and the average price target is 8.16 USD. This implies a price increase of 1049.3% is expected in the next year compared to the current price of 0.71.
The consensus rating for GT BIOPHARMA INC (GTBP) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.